Systematic review and meta-analysis of pulmonary hypertension specific therapy for exercise capacity in chronic obstructive pulmonary disease

Journal of Korean Medical Science

Volumn 28, Issue 8, 2013, Pages 1200-1206

  Park, Jinkyeong ^a   Song, Ju Hee ^b   Park, Dong Ah ^c   Lee, Jae Seoung ^b   Lee, Sang Do ^b   Oh, Yeon Mok ^b  

^a Wonkwang University   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c National Evidence Based Healthcare Collaborating Agency   (South Korea)

Author keywords

Copd; Exercise; Pulmonary hypertension; Vasodilator

Indexed keywords

ANTIHYPERTENSIVE AGENT; BERAPROST; BOSENTAN; DRUG DERIVATIVE; PIPERAZINE DERIVATIVE; PROSTACYCLIN; PURINE DERIVATIVE; SILDENAFIL; SULFONAMIDE; SULFONE; VASODILATOR AGENT;

ANOXIA; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL (TOPIC); EXERCISE; FACTUAL DATABASE; HUMAN; META ANALYSIS; PULMONARY HYPERTENSION; QUESTIONNAIRE; RISK FACTOR;

COPD; EXERCISE; PULMONARY HYPERTENSION; VASODILATOR;

ANOXIA; ANTIHYPERTENSIVE AGENTS; CLINICAL TRIALS AS TOPIC; DATABASES, FACTUAL; EPOPROSTENOL; HUMANS; HYPERTENSION, PULMONARY; PIPERAZINES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; PURINES; QUESTIONNAIRES; RISK FACTORS; SULFONAMIDES; SULFONES;

EID: 84884373956     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.8.1200     Document Type: Article

References (24)

1. Barberà JA, Peinado VI, Santos S. Pulmonary hypertension in chronic obstructive pulmonary disease. Eur Respir J 2003; 21: 892-905.
2. Scharf SM, Iqbal M, Keller C, Criner G, Lee S Fessler HE; National Emphysema Treatment Trial (NETT) Group. Hemodynamic characterization of patients with severe emphysema. Am J Respir Crit Care Med 2002; 166: 314-22.
3. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: role of comorbidities. Eur Respir J 2006; 28: 1245-57.
4. Kessler R, Faller M, Weitzenblum E, Chaouat A, Aykut A, Ducoloné A, Ehrhart M, Oswald-Mammosser M. "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease. Am J Respir Crit Care Med 2001; 164: 219-24.
5. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 2009; 30: 2493-537.
6. Santos S, Peinado VI, Ramírez J, Melgosa T, Roca J, Rodriguez-Roisin R, Barberà JA. Characterization of pulmonary vascular remodelling in smokers and patients with mild COPD. Eur Respir J 2002; 19: 632-8.
7. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, Weitzenblum E, Cordier JF, Chabot F, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023-30.
8. Chin KM, Kim NH, Rubin LJ. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005; 16: 13-8.
9. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
10. Higgins JP, Green S; Cochrane Collaboration. Cochrane handbook for systematic reviews of interventions. Chichester: Wiley-Blackwell, 2008.
11. Lee SD, Seo KW, Lee JY, Huh JW, Choi IS, Park JS, Shim TS, Oh YM, Park IW, Ryu WS, et al. Effect of beraprost sodium in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis 2004; 57: 320-8.
12. Stolz D, Rasch H, Linka A, Di Valentino M, Meyer A, Brutsche M, Tamm M. A randomised, controlled trial of bosentan in severe COPD. Eur Respir J 2008; 32: 619-28.
13. Valerio G, Bracciale P, Grazia D'Agostino A. Effect of bosentan upon pulmonary hypertension in chronic obstructive pulmonary disease. Ther Adv Respir Dis 2009; 3: 15-21.
14. Rao RS, Singh S, Sharma BB, Agarwal VV, Singh V. Sildenafil improves six-minute walk distance in chronic obstructive pulmonary disease: a randomised, double-blind, placebo-controlled trial. Indian J Chest Dis Allied Sci 2011; 53: 81-5.
15. Park JS, Lim HJ, Cho YJ, Lee JH, Yoon HI, Lee CT. Udenafil improves exercise capacity in patients with chronic obstructive pulmonary disease: a prospective study. COPD 2012; 9: 499-504.
16. Rietema H, Holverda S, Bogaard HJ, Marcus JT, Smit HJ, Westerhof N, Postmus PE, Boonstra A, Vonk-Noordegraaf A. Sildenafil treatment in COPD does not affect stroke volume or exercise capacity. Eur Respir J 2008; 31: 759-64.
17. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, et al. Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J 2009; 34: 1219-63.
18. Poor HD, Girgis R, Studer SM. World Health Organization Group III pulmonary hypertension. Prog Cardiovasc Dis 2012; 55: 119-27.
19. Elwing J, Panos RJ. Pulmonary hypertension associated with COPD. Int J Chron Obstruct Pulmon Dis 2008; 3: 55-70.
20. Yamakami T, Taguchi O, Gabazza EC, Yoshida M, Kobayashi T, Kobayashi H, Yasui H, Ibata H, Adachi Y. Arterial endothelin-1 level in pulmonary emphysema and interstitial lung disease: relation with pulmonary hypertension during exercise. Eur Respir J 1997; 10: 2055-60.
21. Barberà JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347: 436-40.
22. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-7.
23. Blanco I, Gimeno E, Munoz PA, Pizarro S, Gistau C, Rodriguez-Roisin R, Roca J, Barberà JA. Hemodynamic and gas exchange effects of sildenafil in patients with chronic obstructive pulmonary disease and pulmonary hypertension. Am J Respir Crit Care Med 2010; 181: 270-8.
24. Minai OA, Chaouat A, Adnot S. Pulmonary hypertension in COPD: epidemiology, significance, and management: pulmonary vascular disease: the global perspective. Chest 2010; 137: 39S-51S.